BAER is a sample, reliable and effective technique for determining auditory functions in the neonates especially changes of early bilirubin toxicity.

PPHN is a genuine problem in MAS-born neonates and is commonly seen in neonates born by unplanned and unmonitored delivery, and the prevalence of PPHN can be reduced by providing good antenatal care, regular follow up of high-risk pregnancy. 2D echocardiography is an important point of care in the diagnosis of PPHN in nursery and should be promoted in nurseries of developing countries as being engaged in developed countries for more reliable treatment.

Hemophilia refers to a group of bleeding disorders in which there is a deficiency of one of the factors necessary for coagulation of the blood. Susceptibility to joint hemorrhage in persons with Hemophilia suggests that the routine assessment of joint health is an important aspect of clinical management and outcome studies assessing the efficacy of treatment. This prospective study was conducted to study joint health status in Hemophilia patients and draw their joint disability score by using Hemophilia Joint Health Score (HJHS). Out of total 56 cases 51 (91.07 %) cases were diagnosed as hemophilia A while 5 cases (8.92 %) were diagnosed as hemophilia B. According to their factor level 44 % cases had severe 36 % had moderate and 20 % had mild disease. Knee joint was the predominant joint affected by hemarthrosis in 67.85 % cases followed by ankle joint (51.7 %) elbow joint (35.7 %), hip joint (12.5 %), shoulder joint (5.3 %) and proximal metacarpophalangeal joint (1.78 %).Out of total 37.5 % patients of hemophilia had developed target joint. Knee joint was the predominant target joint in 28.57 % cases and ankle joint was the target joint in 8.92 % cases. Maximum number of patients (40.47 %) had HJHS score of zero. The mean HJHS score was 6.78 ± 9.04. HJHS score showing significant positive correlation with age of patient (p < 0.0001). Most risky period and most aggravating development of hemophilic joint damage starts from 7 years of age. Therefore, treatment decisions, such as starting prophylaxis, should be tailored according to bleeding pattern and age of patients rather than based on the clotting factor activity levels.

Objective:This study was conducted to validate the use of Acute Physiology and Chronic Health Evaluation II (APACHE II) scoring system in pediatric population in predicting the risk of mortality and to compare the predicted death rate (using APACHE II) with the actual death rate of the patients.Design:Hospital-based prospective study.Setting:Tertiary care Pediatric Intensive Care Unit (PICU) in Western Rajasthan, India.Methods:A total of 100 critically ill children between 1 and 18 years of age admitted to PICU and fulfilling the inclusion criteria were enrolled. APACHE II score was calculated in each patient on the day of admission. The predicted mortality was calculated on the basis of this score.Results:The mean APACHE II score was 21.35 ± 5.76. Mean APACHE II score among the survivors was 16.60 ± 6.12, and mean APACHE II score among the nonsurvivors was 26.11 ± 5.41, and the difference was statistically significant (P = 0.00). The area under the receiver operating characteristic curve for APACHE II score was found to be 0.889 (P = 0.008) indicating good discrimination.Conclusion:APACHE II scoring system has a good discrimination and calibration when applied to a pediatric population.

No abstract